Effects of the etonogestrel-releasing contraceptive implant inserted immediately postpartum on maternal hemostasis: A randomized controlled trial

Thrombosis Research

Volumn 130, Issue 3, 2012, Pages 355-360

  Brito, Milena B ^a   Ferriani, Rui A ^a,c   Meijers, Joost C M ^b   Garcia, Andréa A ^a   Quintana, Silvana M ^a   Silva De Sá, Marcos F ^a,c   Vieira, Carolina S ^a,c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c National Institute of Hormones and Women's Health   (Brazil)

Author keywords

Activated protein C resistance; Contraception; Etonogestrel; Hemostasis; Postpartum; Thrombosis

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; D DIMER; ETONOGESTREL; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD CLOTTING TEST; CONTRACEPTIVE DEVICE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HUMAN EXPERIMENT; IMPLANT; INTERNATIONAL NORMALIZED RATIO; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL; THROMBIN TIME;

ADOLESCENT; BLOOD COAGULATION; CONTRACEPTIVE AGENTS, FEMALE; DELAYED-ACTION PREPARATIONS; DESOGESTREL; DRUG IMPLANTS; FEMALE; HEMOSTASIS; HUMANS; POSTPARTUM PERIOD; PUERPERAL DISORDERS; THROMBOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865268005     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.03.029     Document Type: Article

References (37)

1. R.A. Virkus, E.C. Løkkegaard, T. Bergholt, U. Mogensen, J. Langhoff-Roos, and Ø. Lidegaard Venous thromboembolism in pregnant and puerperal women in Denmark 1995-2005. A national cohort study Thromb Haemost 106 2 2011 304 309
2. E.R. Pomp, A.M. Lenselink, F.R. Rosendaal, and C.J. Doggen Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study J Thromb Haemost 6 4 2008 632 637
3. J.A. Heit, C.E. Kobbervig, A.H. James, T.M. Petterson, K.R. Bailey, and L.J. Melton Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study Ann Intern Med 143 2005 697 706
4. K.A. Bremme Haemostatic changes in pregnancy Best Pract Res Clin Haematol 16 2003 153 168
5. A.H. James Pregnancy-associated thrombosis Hematology 1 2009 277 285
6. N. Macklon, and I. Greer Deep venous flow in the leg in pregnancy and puerperium Contemp Rev Obstet Gynecol 9 1997 93 98
7. I. Greer Thrombosis in pregnancy: maternal and fetal issues Lancet 353 9160 1999 1258 1266
8. B.P. Zhu, R.T. Rolfs, B.E. Nangle, and J.M. Horan Effect of the interval between pregnancies on perinatal outcomes N Engl J Med 340 8 1999 589 594
9. S.O. Rutstein Effects of preceding birth intervals on neonatal, infant and under-five years mortality and nutritional status in developing countries: evidence from the demographic and health surveys Int J Gynaecol Obstet 89 1 2005 S7 S24
10. O. Basso, J. Olsen, L.B. Knudsen, and K. Christensen Low birth weight and preterm birth after short interpregnancy intervals Am J Obstet Gynecol 178 2 1998 259 263
11. A. Conde-Agudelo, and J.M. Belizan Maternal morbidity and mortality associated with interpregnancy interval: cross sectional study BMJ 321 7271 2000 1255 1259
12. C.S. Vieira, R.A. Ferriani, A.A. Garcia, M.K. Gomes, G.D. Azevedo, and M.F. Silva de Sa Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade Hum Reprod 22 8 2007 2196 2201
13. N. Egberg, A. van Beek, C. Gunnervik, S. Hulkko, E. Hirvonen, and U. Larsson-Cohn Effects on the hemostatic system and liver function in relation to Implanon and Norplant. A prospective randomized clinical trial Contraception 58 2 1998 93 98
14. O. Lidegaard, L.H. Nielsen, C.W. Skovlund, F.E. Skjeldestad, and E. Løkkegaard Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9 BMJ 25 343 2011 d6423
15. D. Reinprayoon, S. Taneepanichskul, S. Bunyavejchevin, P. Thaithumyanon, S. Punnahitananda, and P. Tosukhowong Effects of the etonogestrel-releasing contraceptive implant (Implanon®) on parameters of breastfeeding compared to those of an intrauterine device Contraception 62 5 2000 239 246
16. S.T. Truitt, A.B. Fraser, D.A. Grimes, M.F. Gallo, and K.F. Schulz Combined hormonal versus nonhormonal versus progestin-only contraception in lactation Cochrane Database Syst Rev (Online) 2 2003 CD003988
17. M.B. Brito, R.A. Ferriani, S.M. Quintana, M.E. Yazlle, M.F. Silva de Sá, and C.S. Vieira Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study Contraception 80 6 2009 519 526
18. National Institute for Health and Clinical Excellence UK medical eligibility criteria for contraceptive use http://www.cks.nhs.uk/contraception/ management/detailed-answers/uk-medical-eligibility-criteria [Accessed Dec 11, 2011]
19. Centers for Disease Control and Prevention (CDC) Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of contraceptive methods during the postpartum period MMWR Morb Mortal Wkly Rep 60 26 2011 878 883
20. World Health Organization Medical eligibility criteria for contraceptive use 4th ed. 2009 World Health Organization Geneva
21. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice; Long-Acting Reversible Contraception Working Group ACOG Committee Opinion no. 450: Increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy Obstet Gynecol 114 6 2009 1434 1438
22. H.C. Hemker, P. Giesen, R. Al Dieri, V. Regnault, E. de Smedt, and R. Wagenvoord Calibrated automated thrombin generation measurement in clotting plasma Pathophysiol Haemost Thromb 33 1 2003 4 15
23. J. Rosing, G. Tans, G.A. Nicolaes, M.C. Thomassen, R. van Oerle, and P.M. van der Ploeg Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives Br J Haematol 97 1 1997 233 238
24. G. Tans, A. van Hylckama Vlieg, M.C. Thomassen, R.M. Bertina, J. Rosing, and F.R. Rosendaal Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women Br J Haematol 122 3 2003 465 470
25. J.S. Scharfstein, D.R. Abendschein, P.R. Eisenberg, D. George, C.P. Cannon, and R.C. Becker Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. TIMI-5 Investigators. Thrombolysis in Myocardial Infarction Am J Cardiol 78 5 1996 503 510
26. B. Brenner, M. Pery, N. Lanir, A. Jabareen, A. Markel, and J.K. Kaftori Application of a bedside whole blood D-dimer assay in the diagnosis of deep vein thrombosis Blood Coagul Fibrinolysis 6 1995 219 222
27. P.D. Stein, R.D. Hull, K.C. Patel, R.E. Olson, W.A. Ghali, and R. Brant D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review Ann Intern Med 140 8 2004 589 602
28. P.G. Lindqvist, J. Rosing, A. Malmquist, and A. Hillarp Etonogestrel implant use is not related to hypercoagulable changes in anticoagulant system J Thromb Haemost 1 3 2003 601 602
29. C.S. Vieira, R.A. Ferriani, A.A. Garcia, M.K. Gomes, G.D. Azevedo, and M.F. Silva de Sa Transitory reduction of platelet aggregation with the use of etonogestrel implant in healthy women Thromb Haemost 94 3 2005 682 683
30. P. Saha, D. Stott, and R. Atalla Haemostatic changes in the puerperium '6 weeks postpartum' (HIP Study) - implication for maternal thromboembolism BJOG 116 12 2009 1602 1612
31. P. Clark Changes in hemostasis variables during pregnancy Semin Vasc Med 3 1 2003 13 24
32. K. Bremme, E. Ostlund, I. Almqvist, K. Heinonen, and M. Blombäck Enhanced thrombin generation and fibrinolytic activity in the normal pregnancy and the puerperium Obstet Gynecol 80 1992 132 137
33. A.M. Cumming, and R.C. Tait Activated protein C resistance in normal pregnancy Br J Obstet Gynaecol 105 10 1998 1129
34. H. Maybury, J. Waugh, A. Gornall, and S. Pavord There is a return to nonpregnant coagulation parameters after four not six weeks postpartum following spontaneous vaginal delivery Obstet Med 1 2008 92
35. L.B. Finer Henshaw Sk. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001 Perspect Sex Reprod Health 38 2006 90 96
36. United Nations Population Funds (UNFPA) Family Planning: Ensuring that every pregnancy is wanted Available at: http://www.unfpa.org/rh/planning.html [Accessed Apr 11, 2011]
37. E. Jackson Controversies in postpartum contraception: when is it safe to start oral contraceptives after childbirth? Thromb Res 127 Suppl. 3 2011 S35 S39